This enhanced delivery may also improve the therapeutic efficacy of anti-PD-L1 by enabling a more comprehensive blockade of tumor-associated PD-L1, particularly in regions distal to the vasculature where immune effector cells may encounter unbound PD-L1. Here, CD274 is linked to neoplasm.